Veracyte's Q2 2026 earnings surpassed estimates, reflecting robust adoption of its molecular diagnostic assays including the internationally distributed Prosigna Breast Cancer Assay. The company’s business model centers on proprietary test development and commercialization, leveraging both laboratory-developed tests (LDTs) and in vitro diagnostic (IVD) platforms reliant on complex supply chains and payer coverage. Despite steady growth, Veracyte faces notable vulnerabilities from sole-source reagent suppliers, inventory management pressures, and evolving regulatory landscapes impacting reimbursement and international market expansion. Operational scalability and strategic supplier diversification remain critical to sustaining growth momentum alongside ongoing investments in clinical validation and geographic penetration.